Market Overview

UPDATE: Exelixis Announces Proposed Convertible Debt Offering of $225M; Will Grant Underwriters Option to Buy Additional 3M Shares

Related EXEL
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Exelixis' Cometriq Approved in the EU - Analyst Blog

Posted-In: News Offerings


Most Popular

Related Articles (EXEL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free